TP53 and cancer: As both TLR ligands and IFN-alpha are potent immune adjuvants that have been employed for cancer immunotherapy, it is also plausible that some of the immunostimulatory effects of conventional therapies that induce p53 activation are mediated through enhancing the TLR and IFN pathways.